Current data with mammalian target of rapamycin inhibitors in advanced renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 5, Issue 2, 2006, Pages 110-113

  Reddy, G Kesava ^a   Mughal, Tariq ^b   Rini, Brian I ^c  

^a CIG Media Group   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

AP23573; Everolimus; Interferon ; Temsirolimus

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

CLINICAL TRIAL; DRUG EFFECT; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; METASTASIS; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 34250201274     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.026     Document Type: Review

References (23)

1. Negrier S., Escudier B., Lasset C., et al. Re-combinant human interleukin-2, recombi-nant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran-cais d'Immunotherapie. N Engl J Med 1998; 338:1272-1278.
2. Fyfe G., Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose re-combinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696.
3. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(suppl 1): S55-S57.
4. Dutcher J. P. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004; 10(18 pt 2):6382S-6387S.
5. Vignot S., Faivre S., Aguirre D., et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-537.
6. Hudes G., Carducci M., Tomczak P., et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line poor-prognosis patients with advanced renal cell carcinoma. J Clin Oncol 2006; 24(18 suppl):2s (Abstract #LBA4).
7. Zafar Y., Bendell J., Lager J., et al. Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):18s (Abstract #3097).
8. Amato RJ, Misellati A., Khan M., et al. A phase II trial of RAD001 in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24(18 suppl):224s (Abstract #4530).
9. Skotnicki JS, Leone CL, Smith AL. Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res 2001; 7:3749S-3750S.
10. Raymond E., Alexandre J., Depenbrock H., et al. CCI-779, a rapamycin analog with antitumor activity: a phase 1 study utilizing a weekly schedule. Proc Am Soc Clin Oncol 2000; 19:187a (Abstract #728).
11. Atkins MB, Hidalgo M., Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
12. Smith JW, Ko YJ, Dutcher J., et al. Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2004; 23:384 (Abstract #4513).
13. Motzer RJ, Bacik J., Murphy BA, et al. Interfer-on-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
14. Mekhail TM, Abou-Jawde RM, Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
15. O'Reilly T., Vaxelaire J., Muller M., et al. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002; 43:71 (Abstract #359).
16. Lane H., Schnell C., Theuer A., et al. Antiangio-genetic activity of RAD 001, an orally active anticancer agent. Proc Am Assoc Cancer Res 2002; 43:184 (Abstract #922).
17. Huang S., Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3:371-377.
18. Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactiva-tion of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64:252-261.
19. Eisen HJ, Tuzcu EM, Dorent R., et al. Evero-limus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. RAD B253 Study Group. N Engl J Med 2003; 349:847-858.
20. Metcalf C., Bohacek R., Rozamus L., et al. Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proc Am Assoc Cancer Res 2004; 45: (Abstract #2476).
21. Rivera V., Tang H., Metcalf C., et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc Am Assoc Cancer Res 2004; 45: (Abstract #3887).
22. Clackson T., Ca MI, Rozamus L., et al. Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc Am Assoc Cancer Res 2002; 43: (Abstract #LB95).
23. Mita M., Rowinsky E., Goldston M., et al. Phase I., pharmacokinetic (PK), and pharma-codynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily × 5 every other week in patients (pts) with refractory or advanced malignancies. Proc Am Soc Clin Oncol 2004; 23:214 (Abstract #3076).